SCHEMBL722474

SCHEMBL722474

CC(C)C(NP(=O)(Cl)Oc1cc(C(C)(C)C)cc2ccc(C(C)(C)C)cc12)C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.33
NR1H4 Q96RI1 2/20 0.33
CYP2C19 P33261 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
NPSR1 Q6W5P4 2/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CSGALNACT1 Q8TDX6 1/20 0.31
VDR P11473 1/20 0.30
EGLN1 Q9GZT9 2/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
SLC1A2 P43004 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719705 0.89 EGLN1 (0.36) MRGPRX4ALDH1A1EGLN1
SCHEMBL10208284 0.88 MEN1 (0.34) NR1H4MEN1KMT2A
SCHEMBL10208280 0.78 TACR3 (0.32) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL720775 0.76 NR1I2 (0.38) NR1H4CYP2C19NPSR1ALDH1A1MAPT
SCHEMBL721569 0.71 CASP3 (0.43) ALDH1A1LMNAGAAKMT2AEGLN1
SCHEMBL722741 0.69 NR1I2 (0.36) NR1H4CYP2C19MEN1KMT2ACA1
SCHEMBL31355239 0.69 MMP9 (0.45) NPSR1LMNAGAAMEN1KMT2A
SCHEMBL722494 0.67 EGLN1 (0.39) ALDH1A1EGLN1
SCHEMBL720708 0.66 L3MBTL1 (0.45) NPSR1ALDH1A1LMNAGAAMAPT
SCHEMBL721603 0.65 AKR1C3 (0.48) LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2012-03-01 US disclosed
EP-2385951-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS University College Cardiff Consultants, Ltd. (GB) 2011-11-16 EP disclosed
US-20110254856-A1 MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL LG ELECTRONICS INC. (KR) 2011-10-20 US disclosed
WO-2010081082-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections PNP, SAMHD1, MTAP DGAT1 1810/4885NR1H4 1047/4885CYP2C19 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.